Cuiying He
NO.169, TianShan Street
Shijiazhuang, 050035, China
Shijiazhuang, 050035, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.
Journal: Cancer immunology, immunotherapy : CII
Published: April 07, 2026
Expression and prognostic impact of CD73 in classical Hodgkin lymphoma.
Journal: Annals of hematology
Published: January 18, 2026
A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming.
Journal: Journal of translational medicine
Published: October 02, 2025
ATF6 activation promotes tumorigenesis and drug resistance in diffuse large B-cell lymphoma (DLBCL) by regulating the mTOR/S6K signaling pathway.
Journal: Discover oncology
Published: January 10, 2025
The Treatment of Diffuse Large B-Cell Lymphoma (Triple Expression) Involving the Breast, Spleen, and Bone in a Male Patient with Viral Hepatitis B: A Rare Case Report.
Journal: Cancer management and research
Published: July 17, 2023
Association Between Polymorphism in Diabetes Susceptibility Gene Insulin-Like Growth Factor 2mRNA-Binding Protein 2 and Risk of Diffuse Large B-Cell Lymphoma.
Journal: Clinical Medicine Insights. Oncology
Published: June 12, 2023
Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
Journal: Leukemia & lymphoma
Published: October 10, 2022
Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
Journal: BMC cancer
Published: May 13, 2022
Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells.
Journal: BMC cancer
Published: April 26, 2022
Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: April 19, 2022
Nuclear factor of activated T cells as a marker of in vivo low-dose dibenzo[a,h]anthracene exposure.
Nuclear factor of activated T cells as a marker of in vivo low-dose dibenzo[a,h]anthracene exposure.
Journal: Journal of applied toxicology : JAT
Published: February 19, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026